Display options
Cite
MacLean AL, Harrington HA, Stumpf MPH, et al. Epithelial-Mesenchymal Transition in Metastatic Cancer Cell Populations Affects Tumor Dormancy in a Simple Mathematical Model. Biomedicines. 2014;2(4):384-402doi: 10.3390/biomedicines2040384.
MacLean, A. L., Harrington, H. A., Stumpf, M. P. H., & Hansen, M. D. H. (2014). Epithelial-Mesenchymal Transition in Metastatic Cancer Cell Populations Affects Tumor Dormancy in a Simple Mathematical Model. Biomedicines, 2(4), 384-402. https://doi.org/10.3390/biomedicines2040384
MacLean, Adam L, et al. "Epithelial-Mesenchymal Transition in Metastatic Cancer Cell Populations Affects Tumor Dormancy in a Simple Mathematical Model." Biomedicines vol. 2,4 (2014): 384-402. doi: https://doi.org/10.3390/biomedicines2040384
MacLean AL, Harrington HA, Stumpf MPH, Hansen MDH. Epithelial-Mesenchymal Transition in Metastatic Cancer Cell Populations Affects Tumor Dormancy in a Simple Mathematical Model. Biomedicines. 2014 Dec 09;2(4):384-402. doi: 10.3390/biomedicines2040384. PMID: 28548077; PMCID: PMC5344274.
Copy Download .nbib Format: NLM
Share it on

Biomedicines. 2014 Dec 09;2(4):384-402. doi: 10.3390/biomedicines2040384.

Epithelial-Mesenchymal Transition in Metastatic Cancer Cell Populations Affects Tumor Dormancy in a Simple Mathematical Model.

Biomedicines

Adam L MacLean, Heather A Harrington, Michael P H Stumpf, Marc D H Hansen

Affiliations

  1. Theoretical Systems Biology, Department of Life Sciences, Imperial College London, Sir Ernst Chain Building, London SW7 2AZ, UK. [email protected].
  2. Theoretical Systems Biology, Department of Life Sciences, Imperial College London, Sir Ernst Chain Building, London SW7 2AZ, UK. [email protected].
  3. Theoretical Systems Biology, Department of Life Sciences, Imperial College London, Sir Ernst Chain Building, London SW7 2AZ, UK. [email protected].
  4. Department of Physiology and Developmental Biology, Brigham Young University, Provo, UT 84602, USA. [email protected].

PMID: 28548077 PMCID: PMC5344274 DOI: 10.3390/biomedicines2040384

Abstract

Signaling from the c-Met receptor tyrosine kinase is associated with progression and metastasis of epithelial tumors. c-Met, the receptor for hepatocyte growth factor, triggers epithelial-mesenchymal transition (EMT) of cultured cells, which is thought to drive migration of tumor cells and confer on them critical stem cell properties. Here, we employ mathematical modeling to better understand how EMT affects population dynamics in metastatic tumors. We find that without intervention, micrometastatic tumors reach a steady-state population. While the rates of proliferation, senescence and death only have subtle effects on the steady state, changes in the frequency of EMT dramatically alter population dynamics towards exponential growth. We also find that therapies targeting cell proliferation or cell death are markedly more successful when combined with one that prevents EMT, though such therapies do little when used alone. Stochastic modeling reveals the probability of tumor recurrence from small numbers of residual differentiated tumor cells. EMT events in metastatic tumors provide a plausible mechanism by which clinically detectable tumors can arise from dormant micrometastatic tumors. Modeling the dynamics of this process demonstrates the benefit of a treatment that eradicates tumor cells and reduces the rate of EMT simultaneously.

Keywords: cancer growth; chemotherapy; mathematical modeling; metastasis

References

  1. J Cell Biol. 1993 Apr;121(1):145-54 - PubMed
  2. Dev Cell. 2008 Jun;14(6):818-29 - PubMed
  3. Nat Rev Cancer. 2009 Apr;9(4):265-73 - PubMed
  4. J Theor Biol. 2010 Aug 7;265(3):329-35 - PubMed
  5. J R Soc Interface. 2013 Jan 24;10(81):20120968 - PubMed
  6. Cell Stem Cell. 2007 Sep 13;1(3):313-23 - PubMed
  7. Cancer Res. 2013 Jul 1;73(13):3811-6 - PubMed
  8. J Theor Biol. 2010 Oct 21;266(4):708-11 - PubMed
  9. Oncogene. 1991 Apr;6(4):501-4 - PubMed
  10. J Cell Mol Med. 2008 Apr;12 (2):374-90 - PubMed
  11. Cancer Biol Ther. 2005 Sep;4(9):1036-9 - PubMed
  12. Nat Med. 2006 Oct;12(10):1181-4 - PubMed
  13. Semin Cancer Biol. 2012 Oct;22(5-6):374-8 - PubMed
  14. Front Endocrinol (Lausanne). 2012 Oct 23;3:125 - PubMed
  15. Proc Natl Acad Sci U S A. 2014 Mar 11;111(10):3883-8 - PubMed
  16. Cell Death Differ. 2006 Jul;13(7):1238-41 - PubMed
  17. Semin Cancer Biol. 2012 Oct;22(5-6):396-403 - PubMed
  18. Anticancer Res. 1992 Jul-Aug;12(4):1035-53 - PubMed
  19. Cell Stem Cell. 2008 Jun 5;2(6):511-2 - PubMed
  20. Stem Cells. 2014 Feb;32(2):338-48 - PubMed
  21. Cancer Res. 2009 Jul 15;69(14 ):5820-8 - PubMed
  22. Gastroenterology. 2011 Dec;141(6):2218-2227.e5 - PubMed
  23. Neoplasma. 1968;15(6):607-22 - PubMed
  24. Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9951-6 - PubMed
  25. Neoplasia. 2010 Feb;12(2):128-38 - PubMed
  26. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4008-13 - PubMed
  27. Cell Cycle. 2008 Feb 1;7(3):309-13 - PubMed
  28. Curr Opin Cell Biol. 2003 Dec;15(6):740-6 - PubMed
  29. Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12396-400 - PubMed
  30. Cancer Res. 2009 Nov 15;69(22):8814-21 - PubMed
  31. Annu Rev Med. 2007;58:267-84 - PubMed

Publication Types